Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Issue 1 (1st January 2015)

• Record Type: Journal Article
• Authors: Knuf, Markus; Leroux-Roels, Geert; Rümke, Hans. C.; Abarca, Katia; Rivera, Luis; Lattanzi, Maria; Pedotti, Paola; Arora, Ashwani; Kieninger-Baum, Dorothee; Della Cioppa, Giovanni
• Is Part Of: Vaccine. Volume 33:Issue 1(2015)
• Page Start: 174
• Page End: 181
• Publication Date: 2015-01-01
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2014.10.085
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Immunogenicity and safety of MF59-adjuvanted monovalent A/H1N1 pandemic influenza vaccine were assessed in children 3–17 years old.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Long-term antibody persistence after priming and a robust antibody response to booster immunization in all vaccination groups.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">A high proportion reached the stringent HI cut-off titre ≥1:330 postvaccination.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">MF59-adjuvanted monovalent influenza vaccine was generally well tolerated; no serious AEs in the study.</p> </list-item> </list> </p> </sec> </abstract>